Although crizotinib demonstrated excellent efficacy in eradicating EML4-ALK+ NSCLC tumors, recent reports have stressed the evolution of EML4-ALK mutations that are substantially resistant to crizotinib [21-23]. This evidence concerns the gene ALK and non-small cell lung carcinoma.